CHILDRENS CANCER GROUP

该项目建议继续在洛杉矶儿童医院(CHLA)开展全面的儿科肿瘤学计划。该计划旨在通过作为儿童癌症小组(CCG)成员进行临床调查以及独立开展与儿童癌症小组使命直接相关的其他研究来改善儿童癌症的治疗。CHLA是太平洋西南地区的主要儿科转诊中心，拥有全国最大的儿科肿瘤学服务之一。已经制定了一个涉及基础和临床科学家的跨部门计划，并已演变为儿科癌症管理的多学科模式。CHLA是CCG研究患者的主要贡献者之一，该机构的多学科工作人员参与了CCG的所有活动。CHLA研究人员在CCG中的参与使旨在确定任何癌症治疗的最佳模式的定量比较临床研究成为可能。CHLA的独特资源使开发新的治疗方法适用于整个集团。这些研究包括：参与白血病/淋巴瘤、神经肿瘤、骨和软组织肿瘤以及长期随访计划；通过体外和体内药理学研究预测新的剂量方案和已有药物的组合；耐药机制的调查；骨髓外周血和脐带干细胞移植；选定肿瘤的免疫学特征；癌症及其治疗对造血的影响；儿童恶性肿瘤的最佳营养支持；儿童癌症患者及其家庭的心理康复方法；照料者和患者/家庭的教育；儿童恶性肿瘤的流行病学；分子和细胞药理学的临床前研究；肿瘤细胞生物学；癌症发生和化学预防；细胞遗传学。以及体外和体内肿瘤模型系统。社区医生网络在CHLA的赞助下参加CCG，这使那些没有被转介进行初步癌症治疗的儿童能够使用最佳治疗。该项目还提供少数族裔患者继续参加CCG临床试验。通过拟议的更新，CHLA的综合计划将寻求一种儿童癌症的综合和调查方法作为其最终目标。

The project proposes continuation of a comprehensive pediatric oncology program at Childrens Hospital Los Angeles (CHLA). This program is designed to improve the treatment of children with cancer by conducting clinical investigations as a member of the Childrens Cancer Group (CCG) and by independently conducting other research which is directly related to the mission of CCG. CHLA is a major pediatric referral center for the Pacific Southwest and has one of the largest pediatric oncology services in the nation. An interdepartmental program has developed which involves basic and clinical scientists and has evolved into a multidisciplinary model for the management of pediatric cancers. CHLA is one of the major contributors of patients to CCG studies and the multidisciplinary staff at this institution participate in all activities of CCG. Participation of CHLA investigators in CCG enables quantitative comparative clinical investigations aimed at establishing the best mode of any cancer therapy. The unique resources of CHLA permit development of new therapeutic approaches for Group-wide application. These include participation in the Leukemia/Lymphoma, Neuro-Oncology, Bone and Soft Tissue Tumor, and Long-Term Followup Programs; the evaluation of new dose schedules and combinations of established agents predicted by in vitro and in vivo pharmacological studies; investigation of mechanisms of drug resistance; bone marrow peripheral blood and umbilical cord stem cell transplantation; immunological characterization of selected neoplasms; effects of cancer and its treatment on hematopoiesis optimum nutritional support in childhood malignancies; approaches to psychosocial rehabilitation of the pediatric cancer patient and family; education of caregivers and patients/families; epidemiology of childhood malignancies; preclinical studies in molecular and cellular pharmacology; tumor cell biology; carcinogenesis and chemoprevention; cytogenetics; and in vitro and in vivo tumor model systems. A network of community physicians participate in the CCG under the sponsorship of CHLA which enables the use of optimal therapy in children who are not referred for initial cancer care. The project also provides continuation of entry of minority patients on CCG clinical trials. Through the proposed renewal, the comprehensive program at CHLA will seek as its ultimate goal an integrated and investigative approach to childhood cancer.